Skip to main content
PMC home page
Protein Science : A Publication of the Protein Society logoLink to Protein Science : A Publication of the Protein Society
. 1998 May;7(5):1124–1135. doi: 10.1002/pro.5560070506

The role of polar interactions in the molecular recognition of CD40L with its receptor CD40.

J Singh 1, E Garber 1, H Van Vlijmen 1, M Karpusas 1, Y M Hsu 1, Z Zheng 1, J H Naismith 1, D Thomas 1
PMCID: PMC2144015  PMID: 9605317

Abstract

CD40 Ligand (CD40L) is transiently expressed on the surface of T-cells and binds to CD40, which is expressed on the surface of B-cells. This binding event leads to the differentiation, proliferation, and isotype switching of the B-cells. The physiological importance of CD40L has been demonstrated by the fact that expression of defective CD40L protein causes an immunodeficiency state characterized by high IgM and low IgG serum levels, indicating faulty T-cell dependent B-cell activation. To understand the structural basis for CD40L/CD40 association, we have used a combination of molecular modeling, mutagenesis, and X-ray crystallography. The structure of the extracellular region of CD40L was determined by protein crystallography, while the CD40 receptor was built using homology modeling based upon a novel alignment of the TNF receptor superfamily, and using the X-ray structure of the TNF receptor as a template. The model shows that the interface of the complex is composed of charged residues, with CD40L presenting basic side chains (K143, R203, R207), and CD40 presenting acidic side chains (D84, E114, E117). These residues were studied experimentally through site-directed mutagenesis, and also theoretically using electrostatic calculations with the program Delphi. The mutagenesis data explored the role of the charged residues in both CD40L and CD40 by switching to Ala (K143A, R203A, R207A of CD40L, and E74A, D84A, E114A, E117A of CD40), charge reversal (K143E, R203E, R207E of CD40L, and D84R, E114R, E117R of CD40), mutation to a polar residue (K143N, R207N, R207Q of CD40L, and D84N, E117N of CD40), and for the basic side chains in CD40L, isosteric substitution to a hydrophobic side chain (R203M, R207M). All the charge-reversal mutants and the majority of the Met and Ala substitutions led to loss of binding, suggesting that charged interactions stabilize the complex. This was supported by the Delphi calculations which confirmed that the CD40/CD40L residue pairs E74-R203, D84-R207, and E117-R207 had a net stabilizing effect on the complex. However, the substitution of hydrophilic side chains at several of the positions was tolerated, which suggests that although charged interactions stabilize the complex, charge per se is not crucial at all positions. Finally, we compared the electrostatic surface of TNF/TNFR with CD40L/CD40 and have identified a set of polar interactions surrounded by a wall of hydrophobic residues that appear to be similar but inverted between the two complexes.

Full Text

The Full Text of this article is available as a PDF (7.2 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen R. C., Armitage R. J., Conley M. E., Rosenblatt H., Jenkins N. A., Copeland N. G., Bedell M. A., Edelhoff S., Disteche C. M., Simoneaux D. K. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science. 1993 Feb 12;259(5097):990–993. doi: 10.1126/science.7679801. [DOI] [PubMed] [Google Scholar]
  2. Armitage R. J., Fanslow W. C., Strockbine L., Sato T. A., Clifford K. N., Macduff B. M., Anderson D. M., Gimpel S. D., Davis-Smith T., Maliszewski C. R. Molecular and biological characterization of a murine ligand for CD40. Nature. 1992 May 7;357(6373):80–82. doi: 10.1038/357080a0. [DOI] [PubMed] [Google Scholar]
  3. Aruffo A., Farrington M., Hollenbaugh D., Li X., Milatovich A., Nonoyama S., Bajorath J., Grosmaire L. S., Stenkamp R., Neubauer M. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell. 1993 Jan 29;72(2):291–300. doi: 10.1016/0092-8674(93)90668-g. [DOI] [PubMed] [Google Scholar]
  4. Bajorath J., Chalupny N. J., Marken J. S., Siadak A. W., Skonier J., Gordon M., Hollenbaugh D., Noelle R. J., Ochs H. D., Aruffo A. Identification of residues on CD40 and its ligand which are critical for the receptor-ligand interaction. Biochemistry. 1995 Feb 14;34(6):1833–1844. doi: 10.1021/bi00006a003. [DOI] [PubMed] [Google Scholar]
  5. Bajorath J., Marken J. S., Chalupny N. J., Spoon T. L., Siadak A. W., Gordon M., Noelle R. J., Hollenbaugh D., Aruffo A. Analysis of gp39/CD40 interactions using molecular models and site-directed mutagenesis. Biochemistry. 1995 Aug 8;34(31):9884–9892. doi: 10.1021/bi00031a009. [DOI] [PubMed] [Google Scholar]
  6. Banner D. W., D'Arcy A., Janes W., Gentz R., Schoenfeld H. J., Broger C., Loetscher H., Lesslauer W. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell. 1993 May 7;73(3):431–445. doi: 10.1016/0092-8674(93)90132-a. [DOI] [PubMed] [Google Scholar]
  7. DiSanto J. P., Bonnefoy J. Y., Gauchat J. F., Fischer A., de Saint Basile G. CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM. Nature. 1993 Feb 11;361(6412):541–543. doi: 10.1038/361541a0. [DOI] [PubMed] [Google Scholar]
  8. Durie F. H., Fava R. A., Foy T. M., Aruffo A., Ledbetter J. A., Noelle R. J. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science. 1993 Sep 3;261(5126):1328–1330. doi: 10.1126/science.7689748. [DOI] [PubMed] [Google Scholar]
  9. Eck M. J., Sprang S. R. The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. J Biol Chem. 1989 Oct 15;264(29):17595–17605. doi: 10.2210/pdb1tnf/pdb. [DOI] [PubMed] [Google Scholar]
  10. Eck M. J., Ultsch M., Rinderknecht E., de Vos A. M., Sprang S. R. The structure of human lymphotoxin (tumor necrosis factor-beta) at 1.9-A resolution. J Biol Chem. 1992 Feb 5;267(4):2119–2122. [PubMed] [Google Scholar]
  11. Farrah T., Smith C. A. Emerging cytokine family. Nature. 1992 Jul 2;358(6381):26–26. doi: 10.1038/358026b0. [DOI] [PubMed] [Google Scholar]
  12. Graf D., Korthäuer U., Mages H. W., Senger G., Kroczek R. A. Cloning of TRAP, a ligand for CD40 on human T cells. Eur J Immunol. 1992 Dec;22(12):3191–3194. doi: 10.1002/eji.1830221226. [DOI] [PubMed] [Google Scholar]
  13. Grewal I. S., Flavell R. A. A central role of CD40 ligand in the regulation of CD4+ T-cell responses. Immunol Today. 1996 Sep;17(9):410–414. doi: 10.1016/0167-5699(96)10030-x. [DOI] [PubMed] [Google Scholar]
  14. Gruss H. J., Hirschstein D., Wright B., Ulrich D., Caligiuri M. A., Barcos M., Strockbine L., Armitage R. J., Dower S. K. Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease. Blood. 1994 Oct 1;84(7):2305–2314. [PubMed] [Google Scholar]
  15. Hsu Y. M., Lucci J., Su L., Ehrenfels B., Garber E., Thomas D. Heteromultimeric complexes of CD40 ligand are present on the cell surface of human T lymphocytes. J Biol Chem. 1997 Jan 10;272(2):911–915. doi: 10.1074/jbc.272.2.911. [DOI] [PubMed] [Google Scholar]
  16. Karpusas M., Hsu Y. M., Wang J. H., Thompson J., Lederman S., Chess L., Thomas D. 2 A crystal structure of an extracellular fragment of human CD40 ligand. Structure. 1995 Oct 15;3(10):1031–1039. doi: 10.1016/s0969-2126(01)00239-8. [DOI] [PubMed] [Google Scholar]
  17. Kirk A. D., Harlan D. M., Armstrong N. N., Davis T. A., Dong Y., Gray G. S., Hong X., Thomas D., Fechner J. H., Jr, Knechtle S. J. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8789–8794. doi: 10.1073/pnas.94.16.8789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Korthäuer U., Graf D., Mages H. W., Brière F., Padayachee M., Malcolm S., Ugazio A. G., Notarangelo L. D., Levinsky R. J., Kroczek R. A. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature. 1993 Feb 11;361(6412):539–541. doi: 10.1038/361539a0. [DOI] [PubMed] [Google Scholar]
  19. Larsen C. P., Elwood E. T., Alexander D. Z., Ritchie S. C., Hendrix R., Tucker-Burden C., Cho H. R., Aruffo A., Hollenbaugh D., Linsley P. S. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996 May 30;381(6581):434–438. doi: 10.1038/381434a0. [DOI] [PubMed] [Google Scholar]
  20. Lederman S., Yellin M. J., Krichevsky A., Belko J., Lee J. J., Chess L. Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help). J Exp Med. 1992 Apr 1;175(4):1091–1101. doi: 10.1084/jem.175.4.1091. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Macchi P., Villa A., Strina D., Sacco M. G., Morali F., Brugnoni D., Giliani S., Mantuano E., Fasth A., Andersson B. Characterization of nine novel mutations in the CD40 ligand gene in patients with X-linked hyper IgM syndrome of various ancestry. Am J Hum Genet. 1995 Apr;56(4):898–906. [PMC free article] [PubMed] [Google Scholar]
  22. Mohan C., Shi Y., Laman J. D., Datta S. K. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol. 1995 Feb 1;154(3):1470–1480. [PubMed] [Google Scholar]
  23. Naismith J. H., Devine T. Q., Kohno T., Sprang S. R. Structures of the extracellular domain of the type I tumor necrosis factor receptor. Structure. 1996 Nov 15;4(11):1251–1262. doi: 10.1016/s0969-2126(96)00134-7. [DOI] [PubMed] [Google Scholar]
  24. Naismith J. H., Sprang S. R. Modularity in the TNF-receptor family. Trends Biochem Sci. 1998 Feb;23(2):74–79. doi: 10.1016/s0968-0004(97)01164-x. [DOI] [PubMed] [Google Scholar]
  25. Naismith J. H., Sprang S. R. Tumor necrosis factor receptor superfamily. J Inflamm. 1995;47(1-2):1–7. [PubMed] [Google Scholar]
  26. Nicholls A., Sharp K. A., Honig B. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins. 1991;11(4):281–296. doi: 10.1002/prot.340110407. [DOI] [PubMed] [Google Scholar]
  27. Peitsch M. C., Jongeneel C. V. A 3-D model for the CD40 ligand predicts that it is a compact trimer similar to the tumor necrosis factors. Int Immunol. 1993 Feb;5(2):233–238. doi: 10.1093/intimm/5.2.233. [DOI] [PubMed] [Google Scholar]
  28. Ramesh N., Fuleihan R., Ramesh V., Lederman S., Yellin M. J., Sharma S., Chess L., Rosen F. S., Geha R. S. Deletions in the ligand for CD40 in X-linked immunoglobulin deficiency with normal or elevated IgM (HIGMX-1). Int Immunol. 1993 Jul;5(7):769–773. doi: 10.1093/intimm/5.7.769. [DOI] [PubMed] [Google Scholar]
  29. Renshaw B. R., Fanslow W. C., 3rd, Armitage R. J., Campbell K. A., Liggitt D., Wright B., Davison B. L., Maliszewski C. R. Humoral immune responses in CD40 ligand-deficient mice. J Exp Med. 1994 Nov 1;180(5):1889–1900. doi: 10.1084/jem.180.5.1889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Roy M., Aruffo A., Ledbetter J., Linsley P., Kehry M., Noelle R. Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses. Eur J Immunol. 1995 Feb;25(2):596–603. doi: 10.1002/eji.1830250243. [DOI] [PubMed] [Google Scholar]
  31. Spriggs M. K., Armitage R. J., Strockbine L., Clifford K. N., Macduff B. M., Sato T. A., Maliszewski C. R., Fanslow W. C. Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion. J Exp Med. 1992 Dec 1;176(6):1543–1550. doi: 10.1084/jem.176.6.1543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Stamenkovic I., Clark E. A., Seed B. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J. 1989 May;8(5):1403–1410. doi: 10.1002/j.1460-2075.1989.tb03521.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Xu D., Lin S. L., Nussinov R. Protein binding versus protein folding: the role of hydrophilic bridges in protein associations. J Mol Biol. 1997 Jan 10;265(1):68–84. doi: 10.1006/jmbi.1996.0712. [DOI] [PubMed] [Google Scholar]
  34. Xu J., Foy T. M., Laman J. D., Elliott E. A., Dunn J. J., Waldschmidt T. J., Elsemore J., Noelle R. J., Flavell R. A. Mice deficient for the CD40 ligand. Immunity. 1994 Aug;1(5):423–431. doi: 10.1016/1074-7613(94)90073-6. [DOI] [PubMed] [Google Scholar]
  35. Yellin M. J., Sippel K., Inghirami G., Covey L. R., Lee J. J., Sinning J., Clark E. A., Chess L., Lederman S. CD40 molecules induce down-modulation and endocytosis of T cell surface T cell-B cell activating molecule/CD40-L. Potential role in regulating helper effector function. J Immunol. 1994 Jan 15;152(2):598–608. [PubMed] [Google Scholar]

Articles from Protein Science : A Publication of the Protein Society are provided here courtesy of The Protein Society

RESOURCES